• Four cannabis bills introduced on federal level indicates import to government leaders.
• Increased compromise, bipartisanship could lead to significant changes.
• ACP is strengthening position in the sector, currently operating in two states that have passed legislation approving the substance.

Federal cannabis reform has been a roller coaster ride over the past several years, with the introduction of several bills raising hopes for legislative support, especially with a change in the White House seeming to create a more cannabis-friendly atmosphere. But 2021 didn’t bring the much-anticipated change, and many companies operating in the space, including American Cannabis Partners (“ACP”), are looking for this year to be different. “Hope soared with the possibility of federal cannabis reform in 2021,” reported a Feb. 11 “National Law Review” (“NLR”) article (https://ibn.fm/Yt1O8). “But, as 2021 continued on, optimism dwindled as any advancement in federal cannabis reform was hobbled by the inability of Congress to agree on the appropriate level of reform and the proper mechanics for passage. “Specifically, tension rose amongst the elected Democrats on whether to support incremental reform (like access to banks or removal of cannabis from the list of Schedule 1 drugs) or comprehensive legalization with provisions to address social inequities stemming from the legacy of the War on Drugs,” the article continued. “And so 2021 came to an end, and the cannabis industry saw yet another year of failed meaningful change on the federal level.” According to the NLR, however, hope isn’t lost. “If anything, last year saw more bills introduced into Congress (including two new federal legalization proposals) than ever before — clearly indicating its import to our nation’s leaders,” the article reports. “Justice Clarence Thomas from the Supreme Court even subtly advised Congress to address legalization, noting that the Federal Government’s current ‘half in, half out regime’ on cannabis strained the principles of federalism.” In a quick review of existing legislation, the NLR noted four bills — the Secure and Fair Enforcement (“SAFE”) Banking Act, the Marijuana Opportunity Reinvestment and Expungement (“MORE”) Act, the Cannabis Administrative and Opportunity (“CAO”) Act and the States Reform Act (“SRA”) — circulating around Capitol Hill that could lead to significant changes in the cannabis space. The article stated that “Congress should thus focus on forging a compromise or middle ground on these reforms to increase bipartisan support and avoid competing and inconsistent bills floating around, resulting in another year of unwanted (and unnecessary) deadlock. Indeed, the CAO could be an example of such needed compromise — especially if the drafters seriously heed the criticisms and comments provided during the bill’s review period and consider incorporating certain bipartisan elements of the SRA, like a more streamlined and lower rate tax structure.” Like other cannabis companies, American Cannabis Partners is eyeing the federal back-and-forth with more than interest; federal change could have a significant impact on the industry, which currently operates with state-level approvals but without federal support. Yet nationwide, support for cannabis is growing, with a Gallup poll showing that more than two in three Americans (68%) support legalizing the substance (https://ibn.fm/54DHn). ACP is strengthening its position in the sector, currently operating in two states — California and Michigan — that have passed legislation approving marijuana. With a total of 12 cannabis licenses, including 20,000 square feet of cultivation licenses in California and 540,000 square feet of cultivation licenses along with one retail license in Michigan, ACP is contending for first place in the U.S. cannabis industry by following proven strategies that accelerate the company’s assets, operations, expansions and market share. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• People’s ability to learn and make decisions is limited by ability to recall
• The challenge of recalling what has been read has become more difficult with the advent of the digital word
• With Pluaris, the millennia-old challenge of remembering what has been read has become infinitely easier

Five millennia ago, the human mind somewhat miraculously learned how to “connect scratches on clay tables and symbols in cave paintings with sounds of spoken language — in other words, humans learned to read” (https://ibn.fm/cGQWk). Over last 5,000 years, people have built on this basic skill, as reading is the basis of obtaining knowledge. It is this fact, combined with the recognition that people’s ability to learn and make decisions is limited by the ability to recall, that fueled Nowigence’s Inc. (NOWG) development of Pluaris(TM), an off-the shelf, cloud-based, artificial intelligence (“AI”) platform that automates reading and analysis of textual data. “The act of reading activates a symphony of brain activity, involving not only the visual and auditory systems but neural circuits that build meaning, evoke emotion, and encode memory,” states a “Forge” article. “When you read, your brain does much more than simply comprehend the words in front of you: It enables you to empathize with people you’ve never met, to engage with ideas that challenge and inspire you, to imagine other worlds. That is, if you can remember what you’re reading.” The challenge of recalling what has been read has become more difficult with the advent of the digital word. The article goes on to report that “a 2012 review paper by Ziming Liu, a professor of information science at San Jose State University who studies reading behavior, noted that when we read digital text, as opposed to words on paper, we tend to default to skimming over more careful reading. And as screens occupy an increasingly prominent presence in our lives, this kind of distracted skimming has become the new norm of reading, according to the cognitive neuroscientist Maryanne Wolf, author of ‘Proust and the Squid: The Story and Science of the Reading Brain,’ and ‘Reader, Come Home: The Reading Brain in a Digital World.’ “Based on Wolf’s own research on the neuroscience of reading, she thinks this hurried form of reading is sucking much of the benefit — and pleasure — out of one of humanity’s greatest evolutionary leaps forward,” the article continues. “It also explains why so many people struggle to remember what they’ve read even a few moments afterward, she says.” Nowigence has made this struggle infinitely less difficult with the introduction of Pluaris. The game-changing platform allows users to quickly distill knowledge. Fully customizable, Pluaris allows a user to upload websites, text and files; it even automatically monitors public news sources for identified topics of interest. The platform then gathers all the information together and — here’s where it gets good — provides summaries, extracted intelligence, and graphical analysis. Using Pluaris, readers don’t have to wade through all the information themselves, relying on their flawed human recall to remember everything. Instead, they can scan their news feed for key information, view analyzed content for unbiased importance ranking and identify what’s worth drilling down further, reducing the sheer volume of reading material and increasing resources designed to strengthen and support faulty memory. Nowigence is focused on simplifying the challenges of learning and comprehension. The company is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• INND set out to enhance balance sheet and capital structure; enters shareholder-friendly financing arrangements
• Company announces cancellation of almost half of its variable convertible notes ($1.1 million), expects to eliminate remainder in several weeks
• INND remains committed to achieving financing terms that support growth and maximize value for our shareholders

InnerScope Hearing Technologies (OTC: INND), an emerging disruptive leader in the direct-to-consumer hearing technology space, announced that it has successfully renegotiated financing agreements with the holder of its securities, GS Capital Partners, LLC, canceling a series of the variable price convertible notes (https://ibn.fm/bxtG2). As a result of the restructuring transactions, the total principal amounting to $1.1 million held by GS Capital Partners has been eliminated, equivalent to almost half of the company’s outstanding variable price convertible notes. InnerScope expects to eliminate the remainder of its current variable price convertible notes in several weeks in a bid to enhance its balance sheet towards a shareholder-friendly capital structure. As an innovative disruptor in the hearing aid space, InnerScope focuses on providing affordable solutions to millions of Americans suffering from hearing loss. It is estimated that one in eight people in the United States aged 12 years or older has some form of hearing loss in both ears, which is equivalent to 30 million people across the nation. But for many of them, the hearing aids are out of reach due to prohibitive costs. Patients are usually required to shell out around $2,500 as most insurance doesn’t cover hearing aids. For high-end devices, these out-of-pocket costs can amount to over $8,000 (https://ibn.fm/xmQ79). That’s where InnerScope stepped up to the challenge, deploying innovative technology to offer consumers a range of affordable hearing health products, including Bluetooth app-controlled rechargeable hearing aids, hearing and tinnitus vitamins, various hearing aid ear cleaning products, and much more. These hearing products are available for purchase online, allowing consumers to save up to 70% of costs compared to traditional brick-and-mortar clinics. In addition, the products are available through different payment plans, including one-off payments and subscriptions through www.iHeardirect.com. Building on the progress achieved last year, when the company made key strategic moves acquiring two direct-to-consumer hearing aid competitors, iHear Medical and HearingAssist, Walmart’s largest supplier of hearing aids to position itself as a leader in the direct-to-consumer hearing aids space, InnerScope appears to remain poised for further growth. Matthew Moore, President, and CEO of InnerScope, commented upon the announcement of the debt restructuring: “InnerScope is pleased to enter into these shareholder-friendly financing arrangements, which enhances our balance sheet and capital structure. We appreciate the support from GS Capital in completing this transaction, as they continue to be a strong financial partner for us. We will work diligently to achieve the most attractive financing terms that support our growth and maximize value for our shareholders,” concluded Mr. Moore. For more information, visit the company’s website at www.INND.com and the company’s e-commerce websites www.iHeardirect.com and www.HearingAssist.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• In the first quarter of 2022, AREV acquired Wright & Well Essentials Inc., a firm with an extensive hemp and cannabis line of branded products currently sold in Oregon and expanding markets.
• The company’s online sales and marketing platform, Medicine Merchant™, is in the final stages of development; the platform has the potential to revolutionize consumer access to therapeutic interventions and personalized medicine via partnerships with telemedicine providers.
• A recent peer-reviewed study by a member of AREV’s scientific advisory board (“SAB”) has demonstrated the potential utility of specific cannabinoids against all variants of COVID-19.
• Further additions to AREV’s SAB in the second half of 2022 are expected to provide additional opportunities for establishing collaborations with academic institutions and orchestrating the acquisition of promising IP.
• AREV is developing a Ready-to-Use Therapeutic Food (“RUTF”) utilizing proprietary extraction techniques intended to treat inanition which results from the metabolic effects of starvation.
• Regulatory submission of AREV’s RESTORE™ enteral formula in the United States and Canadian markets is scheduled for the second half of 2022, with initial clinical studies expected to commence in Q4 2022.
• Verified Market Research valued the worldwide RUTF market at $363.72 million in 2019 and projected growth to $807.89 million by 2027, expanding at a CAGR of 10.5% for the forecast period.
• The global enteral feeding formulas market was valued at $5.9 billion in 2020 and is expected to expand at a CAGR of 5.9% through 2028, according to Grandview Research.

AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (“SAB”), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant(TM), an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases, and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues. AREV is focused on innovations in biomedicine and maintains a significant footprint in clinical human nutrition utilizing proprietary protein blends and terpenes, complimented with vitamins and minerals. The company has utilized its expertise to design and deliver innovation in therapeutic interventions using its exclusive botanical, fungi and marine compounds to address medical conditions driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV uses its proprietary extractions allowing characterizations from botanical and marine sources in therapeutic foods and medicines that comprise its development pipeline. Development of AREV’s pipeline is fostered by collaborations with academic centers, clinical research organizations and government institutions committed to facilitating discovery of promising new clinical approaches presented in peer reviewed journals. AREV operates under the guidance of its SAB and a growing number of strategic collaborations with CROs and academic research centers, including the Linus Pauling Institute at Oregon State University. AREV is a member of both BIOTECanada and The Biotechnology Industry Organization (“BIO”):

• BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the diverse nature of Canada’s health, industrial and agricultural biotechnology sectors.
• BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and 30+ countries.

Products AREV’s end-product and target categories include therapeutic interventions, botanical drugs, ready-to-use therapeutic food (“RUTF”), enteral nutrition formulas and early-stage small molecule antiviral therapeutics demonstrating novel mechanisms of action. Wright and Well Branded Line Wright and Well Branded Line is the company’s branded line of therapeutic cannabinoid and terpene-based formulations. The topical line includes solutions for burns, wounds, skin disorders and muscle relief, as well as a lubricant for intimacy. The oral line addresses inflammation, heart health, high blood pressure and viral infections. These products are currently produced at CBD99, a licensed processor in Sandy, Oregon. The company also has a strategic relationship with a Canadian licensed hemp and cannabis processor in Vancouver, British Columbia. SUS-TAINN(TM) The company’s products in the RUTF category are branded under SUS-TAINN(TM) (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs). SUS-TAINN(TM) is the flagship line of products stemming from AREV’s collaboration with Voynich Biosciences. RUTFs like SUS-TAINN(TM) are the cornerstone to international famine response and currently represent more than 20 percent of public health commodity procurement spending. SUS-TAINN(TM) is purchased by agencies ranging from the U.S. Department of State AID for International Development to the World Food Program and is distributed by an increasingly substantial number of non-governmental organizations. RESTORE(TM) The company’s enteral nutrition product is branded as RESTORE(TM). For patients experiencing caloric compromise, enteral nutrition, a liquid form of nourishment, is often required. RESTORE(TM), the initial enteral formulation from AREV, is based on organic plant nutrition for patient populations who have demonstrated overt clinical need for rational enhanced caloric intake and micronutrient supplementation. RESTORE(TM) provides a proprietary blend of high-quality proteins, antioxidants, minerals and proven anabolic agents, combined with pre- and probiotics. The company plans to submit for Medicaid formulary inclusion and reimbursement designations in various jurisdictions characterized by the Ryan White CARE Act during the second half of 2022. REV-I1(TM) REV-I1(TM) is the company’s small molecule drug discovery model for phytomedicinalization, based on advanced computational characterization and next generation affinity selection that affords new opportunities in HIV antiretroviral research. REV inhibition offers a critical approach to inhibiting HIV replication and addressing viremia in highly conserved sanctuary regions. Phytomedicinal therapeutic discovery and development offer clinically viable approaches to a wide range of scientific challenges that currently elude successful contemporary interventions. A cornucopia of diverse validated compounds allows AREV to explore a distinguished range of promising approaches that are in stages of pre-clinical validation. Combining AREV’s versatile extraction capability with highly sensitive analytical techniques (LC-MS, MS-MS) is expected to allow new medicinal chemistry to be identified and characterized, leading to therapeutic candidates in the company’s commercial drug discovery platform. Market Overview A report from Verified Market Research valued the global plant protein market at $29.4 billion in 2020 and forecast that it could surpass $162 billion by 2030, which would make up 7.7% of the global protein market, according to a report released in August by Bloomberg Intelligence. The RUTF market was valued at $363.72 million in 2019 and is projected to reach $807.89 million by 2027, growing at a CAGR of 10.5% for the forecast period. The market is primarily driven by the efforts of governments and non-governmental organizations to reduce the rate of severe acute malnutrition. Moreover, changing trends and growing developments related to diet-related deficiencies, as well as increasing incidences of famine and disasters, are likely to fuel the growth of the RUTF market in the near future, according to the report. Management Team Michael Withrow is the founder, chairman and CEO of AREV. He is a successful natural products and technology entrepreneur with more than 25 years of experience. He has started and sold companies and has worked with companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. He has also served as president and CEO of a specialty cannabis technology company. Kevin Phelps, CPA, is a director at AREV. He is CEO and president of Immune Therapeutics Inc., a bio-pharmaceutical company. He began his career with Price Waterhouse before joining Eastman Kodak Company as part of an executive team that successfully spun out the Bio Products Division into Genencor International Inc., an international industrial bio-chemicals company. He later joined Trillium Group, a regional private equity firm, as a partner, where he served on behalf of the firm as CFO of Vaccinex Inc., a vaccine development company, and chairman of AccuMed Inc., a medical device company. He has served as Chairman of Oyagen, a biotech that over the past decade has developed drug discovery methods that have enabled it to explore vulnerabilities in HIV, Ebola and coronaviruses. Denby Greenslade is corporate secretary and interim CFO at AREV. She has served as corporate secretary and director for several companies in the mining, biotech and IT industries and has more than 15 years of corporate secretarial, corporate governance, and securities regulation experience. She graduated from Simon Fraser University with a Bachelor of Arts in Communication. Allan Echino is a director at AREV. He was a founder and director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta. Mr. Echino arranged funding for a licensed producer in the cannabis sector and quickly learned the business and health benefits of cannabis and mushrooms. Mel Maxwell is a director at AREV. During his 40-plus year career, he has founded six companies. His degrees in business and computer science initially took his career toward IT ventures that entailed software development, IT consulting, e-commerce solutions, real estate development, pathogen remediation solutions and wholesale vehicle aggregation. He finds continued enjoyment in consulting with other businesses and entrepreneurs. Scientific Advisory Board Roscoe M. Moore, Jr., DVM, MPH, PhD, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms as chairman of the company’s scientific advisory board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (“IHV”) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV. Dr. Moore served with the United States Department of Health and Human Services (“HHS”) and was responsible, for the last 12 years of his career, for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health (“NIH”) and rising to the rank of Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (“FDA”), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (“CDC”), where he also served as an epidemic intelligence service officer. Robert Melamede, PhD, received his doctorate in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab, where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector. Harold Smith, PhD, is the founder, CEO, and president of Oyagen Inc., a biotechnology company developing therapeutics for various disease states, including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology. Richard Van Breemen, PhD, is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences of the College of Pharmacy at Oregon State University. His research interests include cancer prevention by dietary antioxidants and prostate cancer prevention by the carotenoid lycopene, mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to assess drug metabolism, toxicity and bioavailability. Dr. Van Breemen made The Analytical Scientist’s Power List in 2020 and 2021. His work in biomedical mass spectrometry earned him an initial spot, and he clocked in the Top 100 analytical scientists from around the world on the Power List in 2021. Dr. Blake Hawley is the founder & CEO of Motega Health Inc. Dr. Hawley has worked in animal health, pharma and food across 23 countries and four continents. He holds an MBA from KU and his doctorate in veterinary medicine and zoology degrees from NC State. He serves on multiple non-profit advisory boards, including the KU MBA Advisory Board. Dr. Hawley is a 2017 graduate of Pipeline Entrepreneurs and a graduate of the Village Capital Agricultural 2016 Entrepreneur Cohort. Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes 10 years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the 10 years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition. Uma Dhanabalan, MD, MPH, FAAFP, MRO, CMS, advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey, with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master’s degree in public health from Harvard’s School of Public Health in Boston, Massachusetts, and continued her training at Harvard in occupational and environmental medicine. Special IP Advisor Douglas Sorroco practices in all areas of intellectual property law including patent, trademark, copyright, technology, and e-commerce and assists clients with intellectual property matters requiring litigation, licensing, technology counselling and complex transactions. Mr. Sorroco is ranked in Band 1 (the top band) for intellectual property law by the highly regarded Chambers USA: America’s Leading Lawyers for Business 2021, and he was selected for inclusion in The Best Lawyers in America(R) 2022 for Litigation – Intellectual Property, Litigation – Patent, Patent Law and Technology Law. In 2021, Best Lawyers named him the Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to rank Doug as an IP Star. Mr. Sorroco was selected for inclusion in Oklahoma Super Lawyers 2021 and was also selected by attorney peers for inclusion in Oklahoma Super Lawyers – Rising Stars Edition (2010). For more information, visit the company’s website at www.ArevLifeSciences.com. NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF

• Hollywall looks to capitalize on its background of developing, producing, and acquiring some of the world’s most priced entertainment properties and brands to stamp its position in the industry
• Its success so far can be attributed to its leadership which features a combined shared experience of industry-recognized excellence
• Hollywall remains committed to expanding its business enterprise across industries, cities, states, and government agencies in the United States.
• Over the course of the year, it plans to launch a new global NFT marketplace for its music, film, and software game assets

Founded in 2009 by Darnell Sutton, Hollywall Entertainment (OTC: HWAL) has become one of the most promising enterprises in the telecommunication, infrastructure, media, technology, entertainment, and broadcasting space. With a background of years of developing, producing, and acquiring some of the world’s most priced entertainment properties and brands, this company is well on its way to redefining the entertainment space and stamping its position as an industry leader in other sectors as well. So far, Hollywall has several subsidiaries covering various industries, including but not limited to entertainment, education, 5G, telecommunications, and infrastructure development. The company remains committed to expanding its business enterprise across industries, cities, states, and government agencies in the United States (https://ibn.fm/t1sZe). Its subsidiary, Hollywall Development Company (“HWDC”), for instance, focuses on building, restoring, and creating “smart” cities and communities, leveraging on broadband and 5G networks, tele-education, energy, and other such aspects. On the other hand, HW Vision offers state-of-the-art services targeting the proliferating digital marketplace. These services include web conferencing, video broadcasting, managed internet services, and nationwide unlimited talk, text, and data cellphone plans, among others. Hollywall’s main driving factor has been its human resources, starting from the very top with Mr. Sutton, its Founder, President, and Chief Executive Officer (“CEO”). He is regarded as one of the most exciting master communicators, creative developers, and innovators, with over four decades of work experience. He has his roots in the music recording, publishing, and distribution industries. He has even worked with some of the world’s greatest athletes, including Mike Tyson, Serena Williams, and Floyd Mayweather. On the other hand, Roxanna Green, the company’s Chief of staff, has over 30 years of experience in various aspects such as providing corporate legal and financial guidance, spearheading audits, mergers and acquisition negotiations, and public relations initiatives. These characteristics span across the entire company’s workforce, a factor that allows it to not only push the envelope with innovation but also differentiate itself amongst its peers. Going forward, Hollywall looks to launch a new global NFT marketplace for its music, film, and software game assets as a way to diversify its revenue and capitalize on the growing NFT space. Hollywall Music, a wholly-owned subsidiary of the company, owns legacy music and video collector assets that have been protected for over 20 years. These assets contain some of the rarest and most coveted unpublished records from some of the most legendary artists in the music industry. The company looks to capitalize on this rarity to grow its NFT marketplace and strengthen its brand equity while increasing its revenue. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• StraightUp Resources has optioned or acquired several properties in the historic Red Lake District in Ontario, which has produced over 30 million ounces of gold to date
• The company’s properties in the area include RLX North, RLX South, Belanger, and Ferdinand properties
• Late last year, a senior gold mining company entered into an agreement to acquire Great Bear Resources, one of the success stories of the Red Lake District
• This acquisition, coupled with results from own surveys and the district’s storied history, support StraightUp’s focus in the area

When StraightUp Resources (CSE: ST) (OTCQB: STUPF) optioned mining claims comprising the RLX North, RLX South, and Belanger properties located in the prolific Red Lake District in Ontario, Canada’s Uchi subprovince in 2020, the company expressed optimism at being able to further survey the area and potentially uncover profitable mineralization (https://ibn.fm/V2rf6). In 2021, StraightUp acquired the Ferdinand Gold Property (https://ibn.fm/avBYJ), also located in the Red Lake District, bringing the total of its optioned properties in the area to just under 20,000 hectares. The historic Red Lake District is renowned for having some of the richest gold deposits in the world. According to a report by the Geological Survey of Canada, the Red Lake greenstone belt on which part of the Red Lake mining district sits, had historically produced over 18 million ounces of gold (https://ibn.fm/x8T6q) by the turn of the century. In total, more than 30 million ounces of gold have so far been mined from the area, leading to the successes of gold mining companies like Great Bear Resources. In December last year, Kinross Gold Corporation, a Canadian-based senior gold mining company with mines and projects in North America, South America, Africa, and Russia, entered into a definitive agreement to acquire Great Bear Resources, in a transaction valued at $1.4 billion (other payments may also apply) (https://ibn.fm/ThrE8). Following the acquisition, Kinross would own the Dixie project, one of the most electrifying gold discoveries in the Red Lake mining district, located several kilometers southwest of StraightUp’s properties. Drilling results at the Dixie project have shown the attributes of a prime deposit. This, coupled with the billion-dollar acquisition, reinforce StraightUp’s initial optimism in the Red Lake mining district. In fact, StraightUp’s own ground exploration and heliborne magnetic surveys in the area have evidenced multiple locations of high merit and potential mineralization, including at the Ferdinand project. “We now have confirmation of D2 folding and ultramafic rocks together considered to be a primary control for high-grade gold mineralization in this region, especially the Great Bear Resources Dixie Lake Gold Project. This study represents a transformation of the Ferdinand Gold Project, and we couldn’t be more excited about the road ahead in this unexplored and unappreciated section of the infamous Uchi subprovince,” commented StraightUp President Mr. Mark Brezer as part of the announcement of the interpretation of the Ferdinand property survey data (https://ibn.fm/KXkcg). Similarly, a re-logging and sampling exercise from a 2002 diamond drilling program on the Belanger property revealed multiple areas of mineralization not previously sampled (https://ibn.fm/yczDQ). StraightUp also completed a high-resolution heliborne magnetic survey on its RLX properties in September 2021 (https://ibn.fm/BzOn4). The company intends to combine the interpretation of data from this survey, comprehensive data compilation, and detailed regional structural interpretation to pinpoint the highest priority targets for Orogenic gold occurrences. Last month, StraightUp received an early exploration permit that will help it accomplish some of these objectives (https://ibn.fm/VmKAQ). A public company engaged in the business of exploring and acquiring mineral property assets in North America, StraightUp is keen on maximizing shareholder wealth through mineral discoveries at projects with robust potential. And given the prolific nature of the Red Lake district, where the company has optioned or acquired several properties, StraightUp is indeed working toward this goal. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023
• Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available
• 83% of Americans living with these conditions are open to trying out alternative treatments
• Delic seeks to capitalize on this growing demand for psychedelic alternatives, coupled with ongoing legislative and regulatory changes to grow its brand and increase value for its shareholders

While the psychedelics industry might be in its early stages, its potential is growing tremendously, particularly in the healthcare space. Already, it is estimated that by 2027, this market will be valued at about $10.75 billion. Furthermore, it is estimated that by 2023, the alternative antidepressant drug market, specifically, will be valued at $15.98 billion (https://ibn.fm/PPOym). This growth will be attributed to the ongoing shift from traditional antidepressants to psychedelics, given their higher efficacy and significantly lower relapse rates after treatment. Additionally, the ongoing conversation about psychedelics and their usefulness, particularly for treating mental health diseases, has helped sensitize people about these products and driven up their adoption levels. Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, understands the potential that this industry has and, therefore, seeks to capitalize on it to not only benefit millions of people dealing with mental health issues but also create value for its shareholders. Delic is banking on scientific research to prove the usefulness and effectiveness of psychedelics as an alternative treatment for specific mental conditions. It also relies on customer feedback to help push the conversation and further increase the sensitization of psychedelics for mental health treatment. In a survey conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans who deal with Post-Traumatic Stress Disorder (“PTSD”), depression, and anxiety believe that psychedelic medicine ought to be made available to patients, especially those with treatment-resistant conditions. The study also revealed that 63% of Americans who have used prescription medications to treat these conditions acknowledged that while the medication helped, they still had to deal with residual feelings of their illnesses (https://ibn.fm/Vgx5B). For context, back in 2020, over 7.3 million people were prescribed antidepressants in England alone, representing 17% of the adult population. However, it is estimated that only a third of individuals with depression benefitted then and benefit even today from these prescribed antidepressants, meaning over 4.8 million people found the drugs ineffective. So far, at least 83% of Americans living with these specific conditions are open to trying out alternative treatments that are more effective than mainstream prescription medication and have fewer side effects. Psychedelics such as ketamine, MDMA, and psilocybin are worthy candidates. “One of the key mooted advantages of psychedelics over existing drugs is that they work holistically to make the neuroplastic brain more malleable, therefore freeing people from long-held beliefs and memories- opening them evermore to new concepts and states of mind,” reported an article published in The Guardian. “Thus, they allow the brain to reset and rewire itself, rather than simply dampening down symptoms and even causing serious side effects,” it added. Already, policy toward psychedelics in the health care space is evolving. Legislative and regulatory changes are slowly coming into effect, allowing the psychedelics industry to grow and achieve its full potential. Delic seeks to capitalize on this to grow its brand and define its position in the global psychedelics space. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Projected market growth attributed to degrading air quality levels
• Report notes that “with deteriorating air quality, air purifiers have become a necessity”
• KNOS patented, medical-grade technology has been tested as most effective clean-air solution on the market

In a world becoming increasingly aware of pollution and its significant impact, Kronos Advanced Technologies (OTC: KNOS) and its patented air-purifying system stand on the brink of significant growth and success. Recent reports forecast that the global air purifier market, which was worth $10.7 billion in 2020, will reach an estimated $12.6 billion by 2027, showing an impressive compound annual growth rate (“CAGR”) of 10.6% (https://ibn.fm/goAww). “The market is gaining significant traction because of degrading air quality levels which are leading to severe breathing problems for people,” a BlueWeave Consulting report stated. “Furthermore, rapid industrialization and urbanization, along with the increasing prevalence of airborne diseases, are anticipated to boost the global air purifier market during the forecast period.” According to the World Health Organization, “ambient air pollution accounts for an estimated 4.2 million deaths per year due to stroke, heart disease, lung cancer and chronic respiratory diseases. Around 91% of the world’s population lives in places where air quality levels exceed WHO limits. While ambient air pollution affects developed and developing countries alike, low- and middle-income countries experience the highest burden” (https://ibn.fm/6b4aZ). Since the pandemic started, many people have been spending up to 90% of their time indoors, especially children and work-from-home parents and older adults. As a result, the quality of indoor air has become even more important than outdoor air quality because of the time length of exposure to pollution. According to the EPA, indoor air quality can be up to five times worse than outdoor air quality, especially with regards to airborne pollutants and chemicals. An air purifier, says BlueWeave, is a device “used for removing harmful pollutants and contamination from air to make it breathable. In simpler terms, it improves indoor air quality. With deteriorating air quality, air purifiers have become a necessity. Air purifiers use a sophisticated filtration technology to capture airborne pollutants. The application of this technology offers a wide range of health benefits, such as relieving asthma symptoms, improving sleep quality, neutralizing unpleasant odors, eliminating hazardous asbestos particles, etc., and breathing in clean air can enhance one’s life expectancy.” With air purifiers now being called a necessity, a growing number of companies are entering the space, and it’s becoming increasingly difficult to identify truly superior product offerings. Kronos offers a brand-new patented technology that fully removes harmful allergens, bacteria, viruses (including the flu), and even gases from the air. This revolutionary product far outperforms outdated HEPA filters and eliminates the shortcomings of any other air purifier on the market (https://ibn.fm/G2rEP). Also, Kronos air purifiers are the only ones on the market with washable, reusable filters, eliminating the need to buy costly replacement HEPA filters In fact, Kronos’ medical-grade technology has been tested as the most effective clean air solution on the market. The Kronos AIR 5G(R) devices filter particles down to .0146 micron, far beyond the 3 microns of a traditional HEPA filter. And the Kronos purifiers do more than collect air pollutants — using approximately 30,000 volts, the Kronos AIR 5G air purifiers destroy 99.99% of all airborne bacteria, mold and virus particles. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

Businesses, marketers, social media professionals, and enthusiasts are invited to attend the Social Media Strategies Summit (“SMSS”) on February 23-24th, 2022. This virtual event will be attended by the influential social media industry decision-makers who will share their valuable inputs for successful digital marketing strategies. SMSS is a pioneer in hosting social media conferences that benefit a spectrum of businesses and services to engage with a targeted audience of decision-makers. Senior marketing professionals will share valuable information and knowledge on time-tested social media strategies that they successfully employ for targeting greater audience reach. Attendees can leverage this social media platform for communicating and interacting with their peers and experienced marketing professionals. The featured sessions at the conference include learning experiences by Lauren Thomas, Senior Manager, Communications & Social, Intuit, discussing strategic platform strategy on TikTok, the best practices for creating engaging content on TikTok, and ways to engage with TikTok content creators. Attendees will also learn how to measure social media success and how to prioritize KPIs to make social media analytics work for them. Further, as social media marketing is a booming industry, participants will also gain insights into key factors for deciding organic vs paid strategies. 6 Reasons For Attending #SMS Summit in 2022:

• Learn the intricacies of a successful social media strategy for your brand
• Develop efficient social media tools for transforming the social media strategy of your company
• Assess and evaluate your current social media strategies through discussions, feedback and peer-to-peer learning at the conference
• Witness the value-added sessions by influential industry decision-makers to inspire your innovation
• Reframe your social strategy as per current trends as brand experts discuss successful brand campaigns
• Improve your existing skill sets and improve your processes to accelerate your career

The event will witness the presence of eminent speakers who are thought leaders, decision-makers who will share their experiences and proven social media strategies that will help companies boost their social media presence for brand success. On registration, participants can avail access to 10 live sessions with 6 additional on-demand sessions to watch on your own time, access to ALL presentation videos and slides for a full 6 months post-event, along with Live chat and speaker Q&A, 1:1 meetings, and video-chat networking lounge. To learn more, please visit https://ibn.fm/EXzDG.

• NASDAQ’s proposal for more diversity (one female and one ethnic/LGBTQ+ member) was approved by the SEC in 2021
• Knightscope’s board of directors includes CEO and Chairman of the Board William Santana Li and six female independent directors
• The company’s autonomous security robots provide 24/7/365 security by observing, recording and reporting through the Knightscope Security Operations Center interface

California was the first state to pass a law to require more diversity on corporate boards. The law, passed in 2019, requires that board members of publicly-held California-based companies have at least one female director by the end of 2019 and three by the end of 2021. In addition, the inclusion of “underrepresented populations” is also a requirement, with anyone found in violation risking a fine of $300,000. Since then, other states have followed in California’s footsteps, including Washington, Massachusetts, New Jersey, and Illinois – which only requires the disclosure of female and minority board members. The approach was also implemented worldwide, with countries such as Iceland, Norway, Israel, Italy, France, Belgium, and Finland all requiring quotas for female board members that range from 33 to 50 percent (https://ibn.fm/St222). In August 2021, the Securities and Exchange Commission (“SEC”) approved NASDAQ’s proposal to boost the number of women, racial minorities, and LGBTQ+ people on the corporate boards of U.S. companies. The new policy will require that boards have at least one woman and one minority/LGBTQ+ individual on the board, and companies will need to disclose these statistics publicly. Those with less than five governing board members will only be required one diverse member on the board. Although NASDAQ will not delist those companies that do not comply, they will require them to explain why they have not upheld the new ruling publicly. As of June 2020, 82.5% of directors among Fortune 500 company boards were white, according to a study by the Alliance of Board Diversity and consulting firm Deloitte. The number of racial minorities in these companies only rose by 1% between 2018 and 2020 – but the number of women in these companies rose 4%, totaling 26.5%. Between July 2020 and May 2021, 32% of newly elected board members in the S&P 500 were black, up 11% from the previous year, based on an analysis by ISS Corporate Solutions (https://ibn.fm/d8t9c). One California company has been disrupting the boundaries of traditional governance boards since becoming public at the end of January. Knightscope (NASDAQ: KSCP) is a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”). The company has six independent directors listed on its board – all of them women, which makes up 86% of the entire board, and 43% of the board is a minority (African-American, Latin, Asian). Headed by Chairman and CEO William Santana Li (who is half Latin and half Asian), Knightscope’s 100% diverse board includes:

• Kristi Ross – Co-Founder, Co-Chief Executive Officer, and President of tastytrade, Inc.
• Linda Keene Solomon – Chief Executive Officer of Wellspring Solutions, Inc.
• Jackeline V. Hernandez Fentanez – Founding member of Plug and Play
• Patricia “Patty” L. Watkins – Managing Partner of M.O.R.E. SALES Advisors
• Patricia “Trish” Howell – Vice President of Manufacturing for Avail Medsystems, Inc.; Audit Committee Chair, and Independent Director of CVR Medical
• Suzanne Muchin – Clinical Associate Professor at Kellogg School of Management; Co-Founder and CEO of Bonfire

You can learn more about the Knightscope Board at www.Knightscope.com/board Knightscope’s advanced physical security technologies offer a range of industries a new and efficient approach to security – fully autonomous security robots (“ASRs”). These ASRs provide 24/7/365 security by observing, recording and reporting through the Knightscope Security Operations Center (“KSOC”) user interface. The KSOC provides real-time access to data that features a 360-degree eye-level HD video stream, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. Three ASR models are available at the time – K1 stationary machine, K3 indoor machine, and K5 outdoor machine – and each of them comes with the KSOC software required for control and interaction.  The technology is offered on a cost-effective Machine-as-a-Service (“MaaS”) business model driving a recurring revenue stream addressing the recurring societal problem of crime. For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com, and if you have a need for the subscription-based physical security service, you may request a private demonstration of the technology at www.Knightscope.com/demo.  NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP